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Abstract
Inflammatory bowel diseases (IBD) profoundly affect quality of life and have been gradually
increasing in incidence, prevalence and severity in many areas of the world, and in children
in particular. Patients with suspected IBD require careful history and clinical examination,
while definitive diagnosis relies on endoscopic and histological findings. The aim of the pres-
ent study was to investigate whether the alveolar air of pediatric patients with IBD presents a
specific volatile organic compounds’ (VOCs) pattern when compared to controls. Patients
10–17 years of age, were divided into four groups: Crohn’s disease (CD), ulcerative colitis
(UC), controls with gastrointestinal symptomatology, and surgical controls with no evidence
of gastrointestinal problems. Alveolar breath was analyzed by ion molecule reaction mass
spectrometry. Four models were built starting from 81 molecules plus the age of subjects as
independent variables, adopting a penalizing LASSO logistic regression approach: 1) IBDs
vs. controls, finally based on 18 VOCs plus age (sensitivity = 95%, specificity = 69%, AUC =
0.925); 2) CD vs. UC, finally based on 13 VOCs plus age (sensitivity = 94%, specificity =
76%, AUC = 0.934); 3) IBDs vs. gastroenterological controls, finally based on 15 VOCs plus
age (sensitivity = 94%, specificity = 65%, AUC = 0.918); 4) IBDs vs. controls, built starting
from the 21 directly or indirectly calibrated molecules only, and finally based on 12 VOCs
plus age (sensitivity = 94%, specificity = 71%, AUC = 0.888). The molecules identified by
the models were carefully studied in relation to the concerned outcomes. This study, with
the creation of models based on VOCs profiles, precise instrumentation and advanced sta-
tistical methods, can contribute to the development of new non–invasive, fast and relatively
inexpensive diagnostic tools, with high sensitivity and specificity. It also represents a crucial
step towards gaining further insights on the etiology of IBD through the analysis of specific
molecules which are the expression of the particular metabolism that characterizes these
patients.
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Introduction
Inflammatory bowel diseases (IBDs), which comprise Crohn’s disease (CD) and Ulcerative
Colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract that profoundly
affect the quality of life and have been gradually increasing in incidence, prevalence and sever-
ity in many areas of the world. [1–5] Around 25% to 30% of all diagnoses are made in the first
two decades of life. [1,6] Among childhood onset-IBD, there is an especially rising incidence
of CD that is approximately 3/100,000. [3] The prevalence in the pediatric population (< 20
years of age) is reported to be 58/100,000 for CD and 34/100,000 for UC. [4]
Failure to diagnose and induce disease remission during the peri-pubertal period can have
significant consequences such as missed pubertal growth spurt and reduced adult height, [7]
or low bone mineral density leading to an increased long-term risk of fractures. [8]
Patients with suspected IBD require a careful history and clinical examination along with
blood tests. However, normal laboratory investigations cannot exclude a diagnosis of IBD.
[6,9] Definitive diagnosis relies on endoscopic and histological findings. [9] Gastrointestinal
endoscopy and colonoscopy should be undertaken in any patient with suspected IBD. [9] Mul-
tiple mucosal biopsies should be obtained for histopathological examination. [6] Other ways of
investigating the small bowel in CD are capsule endoscopy and magnetic resonance imaging.
They can provide details about the extent of inflammatory changes in the mucosa and are also
able to identify smaller superficial mucosal lesions without radiation. [2] The only non-inva-
sive high sensitivity (73.5–100%) marker for gut inflammation is fecal calprotectin, which has,
however, low specificity (65.9–97.9%). [10]
No simple, fast and cheap test for diagnosing and monitoring intestinal inflammation in
IBD is available at present.
There is strong evidence to suggest that particular disorders that increase oxidative stress
can be detected by molecular analysis of exhaled air. [11] Breath analysis represents a new
diagnostic technique that started in the 1970s when Pauling et al. detected approximately 250
components in human breath using gas chromatography. [12] Various analytical techniques
have been used to detect exhaled VOCs: the most commonly used are mass spectrometry
(MS)-based techniques, [11] among which the leading is gas chromatography (GC-MS), which
are followed by the use of nanoparticles sensor arrays. [13] Several studies have shown that
VOCs profile can be helpful to diagnose several diseases, [14] including lung cancer, [15,16]
breast cancer, [17,18] diabetes mellitus, [19] hepatic cirrhosis, [20] active tuberculosis, [21]
cystic fibrosis [22] and preeclampsia. [23]
Metabolic derangement in IBDs was initially studied using the headspace of feces and
urine. Probert compared the VOCs profile in the headspace gas emitted from fecal samples
from IBD patients, healthy subjects and patients with infectious diarrhea. He found a specific
pattern of compounds strongly associated with the alteration of intestinal homeostasis. [24]
Another study demonstrated the potential application of fecal VOC analysis in diagnosing IBD
in a pediatric cohort. [25] The headspace of urine in IBD patients showed a different VOC pro-
file, with the suggestion that altered gut permeability is reflected in urinary profiles. [26]
A recent review investigated the role of VOCs breath analysis in the diagnosis of gastroin-
testinal diseases, including IBDs. [27] Lipid peroxidation appears to be the main mechanisms
behind the changes in the VOCs profile in both CD and UC patients. Pentane, ethane, propane
and isoprene appear to present consistently higher levels in patients with IBD compared to
controls. Also fractional exhaled nitric oxide (FENO) measurements in patients with Crohn’s
disease has been investigated as a marker of active inflammation. Significantly higher levels of
FENO were observed in CD patients with clinically active disease compared to CD patients in
clinical remission. [28]
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Hicks et al. has shown that exhaled breath VOCs profiling can distinguish IBDs adult
patients from healthy controls. [29] VOCs belonging to the aldehyde group (butanal and nona-
nal) are elevated in both UC and CD, and are, especially in the latter, a marker of oxidative
stress. Also volatile sulfur-containing compounds (dimethyl sulfide and hydrogen sulfide)
were shown to be able to distinguish CD patients from UC and controls. Hydrogen sulfide was
significantly lower in CD, while ammonia was significantly lower in UC compared to healthy
controls. [29]
Only one study verified the presence of a specific VOCs pattern in the alveolar air of chil-
dren with IBD, [30] and found that the values of three specific VOCs (1-octene, 1-decene, E-
2-nonene) could discriminate between IBD and controls. However, no distinctive pattern
could be identified for CD and UC.
The primary aim of our study is to investigate whether pediatric patients with IBD have spe-
cific VOCs patterns when compared to control subjects. Patients will be divided into four
groups: CD, UC, controls with gastrointestinal symptomatology, and surgical controls with no
evidence of gastrointestinal problems. Having identified specific VOCs patterns, the second
aim of the study was to try to understand how discriminating molecules could be linked to the
IBDs.
Methods
Cases and controls
The study was approved (RC 1/12) by the Technical Scientific Committee of the Institute for
Maternal and Child Health—IRCCS “Burlo Garofolo” of Trieste, Italy. All enrolled patients
and/or their parents or caregivers signed an informed consent form prior to their enrollment.
From June 2012 to June 2013, we enrolled patients aged 10–17 years affected by IBD (both
ulcerative colitis and Crohn’s disease) (“cases”), other gastrointestinal diseases (“gastro con-
trols”) and subjects without gastrointestinal problems (“healthy controls”). Diagnoses of ulcer-
ative colitis and Crohn’s disease were made according to the ESPGHAN and NASPGHAN
guidelines for the pediatric population. [31] All cases and gastro controls were enrolled at the
outpatients service of the Gastroenterology Unit of the Institute for Maternal and Child Health
—IRCCS Burlo Garofolo of Trieste, Italy. Subjects without gastroenterological problems were
enrolled at the Day Surgery among patients hospitalized for issues not related to gastroenterol-
ogy (orthopedic, otolaryngology, eye, dental, urology surgery): these patients were all carefully
evaluated to exclude those with gastrointestinal symptoms. At the time of air sampling, which
was carried out in the morning, all subjects has been fasting at least since midnight. Breath
sampling in all day surgery controls was done pre-operatively. Additional information on their
medical history and ongoing therapies was collected. Patients with IBD were also evaluated
using the Pediatric Ulcerative Colitis Activity Index (PUCAI) [32], the Pediatric Crohn’s Dis-
ease Activity Index (PCDAI) [33]. Both indexes are reported in Tables A and B of S1 Text. The
Paris disease classification has been used to classify IBD cases for localization and to capture
the dynamic features of the disease phenotype. [34]
Alveolar air sampling
For breath sampling, subjects were asked to exhale once through a device called Bio–VOC™
breath sampler (Markes International Ltd., Llantrisant, UK) into a 20 ml volume glass vial (the
Bio–VOC™ sampler avoids rebreathing). All glass vials had been previously sterilized and
sealed individually. After completing exhalation, the glass vial was crimped airtight with the
appropriate crimp cap. Two samples of expired air were collected for each subject to increase
the possibility of obtaining at least one properly sealed sample. In addition, a glass vial was
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sealed with environmental air present at the same time and in the same place as each exhaled
air sample. Vials were preserved at –20˚C up to the moment of the Mass Spectrometry (MS)
analysis. Fig 1 shows the steps of the sampling procedure and VOCs analysis.
Equipment
VOCs in alveolar breath and in environmental samples were analyzed using the “Airsense”
Ion Molecule Reaction–Mass Spectrometry (IMR–MS) from V&F (medical development
GmbH, Absam, Austria). The soft ionization process was performed via ion beams interact-
ing with the gas sample, as already reported by Hormuss and colleagues. [36] The vials were
placed in a V&F autosampler, heated up to 65˚C and dynamically transferred to the V&F
Airsense. The spectrometer measures the concentration of products in a sample. These
products mainly represent molecules existing in traces in the sample but may, in some cases,
also represent fragments of other molecules generated by the soft ionization occurring in the
instrument.
The concentration of 97 volatile compounds (masses from 16 to 123) was measured in all
samples. Thirty-one compounds had a known chemical structure (directly or indirectly cali-
brated with calibration gasses), while 66 groups of products were known only for their molecu-
lar weight (MW). A direct calibration was carried out for 23 chemical compounds: Acetylene,
Ethane, Formaldehyde, Methanol, Acetonitrile (ACN), Formic Acid, Acetic Acid, Ethylene,
Propene, Acetaldehyde, Butadiene, Butanol, Methyl Ethyl Ketone (MEK), Acetone, n–Propa-
nol, Isoprene, n–Pentane, Benzene, n–Hexane, Toluene, n–Heptane, CO2 and O2. Our aim
was to calibrate a panel of compounds between 16 and 123 Dalton, including petroleum-
related products, micropollutants measured by various authors, molecules derived from
Fig 1. Explanation of the sampling procedure and the VOCs measurement by IMR-MS. A) breath sampler with disposable cardboard
mouthpiece and the pushrod; B) connect the pushrod to the sampler and flush the sampler by pulling and pushing the rod in and out two or three
times; C) remove to rod and connect the disposable mouthpiece to the sampler, placing the glass vial on the other side; D) have the patient breath
normally and then keep exhaling trough the mouthpiece until their lungs are emptied; E) crimp airtight the glass vial with the appropriate crimp cap;
F) throw away disposable mouthpiece and clean the breath sampler by flushing it two/three times using the pushrod; G) the glass vial, preserved at
–20˚C, is analyzed with the IMR-MS method, schematized here (reported from Defoort and colleagues [35]) and described in detail in Hornuss and
colleagues [36].
https://doi.org/10.1371/journal.pone.0184118.g001
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human or animal metabolism (acetone, isoprene, n-pentane), molecules that are present in
foods or their metabolites (acetic acid, formic acid, formaldehyde, methanol), and products
found in alveolar air by various authors and that could have useful biological meanings. These
products provided indications on the quality of the results obtained.
CO2 and O2 were measured by a specific detector with variation coefficients lower than 1%.
For the reported compounds, the reproducibility of the assays was assessed by analyzing 30
environmental air samples collected in the same room, in six replicates on five different days
over a three weeks period. The intra-assay (comparison of samples collected on the same day)
coefficients of variation were less than 10% for Ethane, Formaldehyde, Methanol, ACN, For-
mic Acid, Ethylene, n-Butanol and n–Pentane. For the other products the intra-assay coeffi-
cients of variation were less than 20%, except for Acetone (24%) and Acetic Acid (35%). The
inter-assay (comparison of samples collected on different days) coefficients of variation were
lower than 10% for Formaldehyde, Methanol, ACN, Formic Acid and n-Butanol, and lower
than 20% for the other products. The inter-assay coefficients of variation were 27% for Ace-
tone and Ethane, and 40% for Acetic Acid. Coefficients of variation of ppb concentrations are
considered to be highly satisfactory if below 20%. The values above 20% we obtained can be
considered as acceptable.
Benzene was used for the indirect calibration of other eight molecules: Methane, HNO2,
N2O, NO, H2S, H2O, Ammonia (NH3), Sulfur Dioxide (SO2). This model represents a semi–
quantitative calibration procedure which is commonly used in (multicomponent) analytical
devices.
The measured VOCs are given as absolute concentrations (ppm) and as volume percent for
CO2 and O2, these latter gases being used to provide information on the quality of environ-
mental or alveolar samples. CO2 values lower than 2% in alveolar air samples were presumed
to be associated to missampling or to inadequate vial crimping: these samples were excluded.
Statistical analyses
We first described the sample of controls and patients with Crohn’s disease (CD) and with
ulcerative colitis (UC). We then graphically represented, as Δ between medians of exhaled and
environmental air, the comparison between the VOCs profile of all breath samples and that of
all the environmental samples. We also graphically compared breath samples of CD and UC
patients with controls values, again as Δ between breath samples of CD or UC patients and
controls.
In order to establish if the VOCs were to be considered endogenous or exogenous, we ran a
t–test for each of the 98 compounds, and verified whether the values in the environmental air
samples were significantly higher than in the exhaled breath samples. If so, the “exogenous”
compound was excluded from the regression models exposed below. Compounds with
higher concentrations in the environment if compared to the exhaled breath have a partial
pressure inducing pulmonary absorption, and their alveolar concentrations will be in constant
equilibrium with the ones in the environment. Consequently they will substantially not be
informative on the physiopathological conditions of the organism. The choice of focusing
on compounds with alveolar concentrations higher than environmental ones was meant to
restrict the panel to products primarily associated with specific metabolic (physiological or
pathological) conditions, avoiding interferences attributable to “environmental pollutants”.
The exclusion was also justified by the fact that in the environmental air samples few of these
exogenous molecules had significantly different values in cases and controls, probably due to
environmental differences in the outpatient clinic in which samples from the two groups were
taken.
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For the elaboration of a predictive model that might allow for future generation of a diag-
nostic tool, and considering the large number of independent variables involved in the analy-
sis, we decided to adopt a Lasso (Least Absolute Shrinkage and Selection Operator) logistic
regression (LLR) approach. [37,38] By shrinking the estimates of the regression coefficients
towards zero relative to the maximum likelihood estimates, this penalizing estimation
method prevents any overfitting that may arise as a consequence of either collinearity or high–
dimensionality of independent variables. This method allows to shrink the regression coeffi-
cients adopting a tuning parameter λ, which controls the amount of shrinkage that is applied
to the estimates. In addition, the shrinkage of some coefficients to zero reduces the number of
covariates in the final model, allowing us to avoid using classical stepwise regression methods,
which are strongly criticized for their lack of consistency. [39] Independent variables (mole-
cules) were standardized to allow for optimal penalization.
In particular, we adopted an iterated LLR approach. [40] First, we used a 50–fold cross–vali-
dated LLR to reduce the number of variables in the model, eliminating all variables if coeffi-
cients were 0. Then we used this set of variables in a two–step iterated 50–fold cross–validated
LLR, [40] in which the first LLR generated penalized weights to be used in a second adaptive
LLR. [41]
LLR was used to generate four different models with the VOCs remaining after the exclu-
sion of the exogenous ones, plus age as independent variables, diverging in terms of dependent
variable: 1) IBD patients vs. controls (gastroenterological and healthy); 2) IBDs vs. gastroenter-
ological controls; 3) Crohn’s disease (CD) patients vs. patients with ulcerative colitis (UC); 4)
the first model was then replicated using only the molecules that had been directly or indirectly
calibrated, with the intent of generating a model with unambiguously identified molecules.
The intent of the first model is to try and separate IBDs from a “real population” mix, made of
children with and without gastrointestinal problems. The second model aims at reproducing
the situation that is found in a gastroenterology outpatient clinic. The third model represent a
second step in diagnosis, moving from the identification of IBD to the separation between CD
and UC, while also addressing the question of the differences in VOCs profiles between CD
and UC patients. The fourth model has been deprived of the unknown molecules. This repre-
sents a limitation compared to the first model, but, being based on known molecules only, this
latter model can be replicated more easily.
What varies from model to model is the way in which the λ value was selected in the first
LASSO. In some cases, even when we had the possibility of selecting an optimal λ, based on
the graph representing the penalization of the variables involved, we chose to adopt a less
penalizing λ, obtaining as a result a larger number of variables to be included in the iterated
LASSO procedure.
Analyses were carried out with Stata/IC 11.2 (StataCorp LP, College Station, TX, USA) and
with R version 2.15.1 (The R Foundation for Statistical Computing, Vienna, Austria), and
“penalized” (Goeman JJ. Penalized R package, version 0.9–42) and “polywog” (Kenkel B,
Signorino CS. Bootstrapped Basis Regression with Oracle Model Selection, version 0.2–0) R
packages.
Results
A total of 234 subjects was enrolled in the study over a one year period: 67 cases (33 UC and
34 CD patients), and 167 controls (65 gastrointestinal controls and 102 healthy controls)
(Table 1). After receiving quick and simple instructions, all subjects carried out the air sam-
pling without any difficulty. Cases and gastroenterological controls are described in Tables A
to C in S2 Text.
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First, we analyzed the differences in concentration of the 97 molecules present in the envi-
ronment and in the alveolar air of cases and controls, and excluded from further analyses 13
molecules with significantly lower values in the alveolar air compared to environmental air
(M27, Ethane, Formaldehyde, Methanol, Formic Acid, SO2, NO, H2S, M31, M32, M48, M49,
M80), which were thus defined as exogenous. Some of the excluded compounds, such as
hydrogen-sulfide, could also have an endogenous nature. As explained above, however, the sig-
nificantly higher presence of such compounds in environmental air if compared to exhaled
breath would mean that most of the expired component would not be endogenous, and would
thus be difficult to interpret.
Data on H2O, O2 and CO2 concentrations were employed to assess whether the samples
had been collected properly, but were excluded from the models because of their particularly
cumbersome presence. We thus remained with the 81 molecules (Table 2) listed in Fig 2,
which shows the difference between median values of alveolar and environmental air, with val-
ues standardized to environmental air. Fig 3 also shows the VOCs profiles of median values of
CD and UC patients compared with control subjects, with values standardized to the median
of control subjects. Mean values and 95% confidence intervals for these molecules, as identified
in environmental air samples and in exhaled breath samples of cases and controls, are reported
in S1 Table.
The 81 molecules plus the age of subjects were considered as independent variables in all
four models. The results of the models are reported below.
IBD (CD + UC) vs. controls (surgical + gastroenterological)
The first model is based on the comparison between all IBDs without distinction and all con-
trols. The final resulting model comprises 18 VOCs plus age in years, and has the following
formula:
• predicted probability = 1/(1+exp(– (–1.7610965 +0.4349465Age –2.1312841Methane –
0.2097137NitrousAcid +0.0011512AceticAcid +0.0004002Ammonia +0.0058942Propene
+0.0008888Acetaldehyde –0.0232373MethylEthylKetone –0.1222845M69–0.0266032M74
+0.1684388M76–0.0489416M79 +0.0425079M81–0.0280041M89 +0.0793372M99–
0.1427593M105–0.0132398M107–0.0539797M115 +0.1597398M118)))
Confidence intervals and standard error of the coefficients are reported in Table 3. The
Area under the ROC curve (AUC) was 0.925 (95%CI: 0.889–0.961) (S1 Fig) and the perfor-
mance of the model for sensitivity levels above 90% are reported in Table 4. The model could
detect 96% of all IBD cases with a specificity of 69% (65% in gastro controls and 73% in
surgical controls). In this case, 23 out of 65 gastro controls result as being false positives. No
significant differences in the distribution of the diseases was found among these (Table 5).
However, when the diseases are classified based on the presence (or plausibility) of an ongoing
Table 1. Description of the sample of inflammatory bowel disease cases and controls enrolled in the
study (children 10 to 17 years of age).
UC (33) CD (34) Gastro Ctrls (65) Healthy Ctrls (102)
Sex F 15; M 18 F 16; M 18 F 27; M 38 F 45; M 57
Age 14 (12–16) 15 (14–16) 12 (11–15) 13 (11–14)
F: Females; M: Males; UC: Ulcerative colitis; CD: Crohn’s disease; Gastro Ctrls: gastroenterological
controls; Healthy Ctrls: Healthy controls. Age is expressed in years as median and interquartile range in
parenthesis.
https://doi.org/10.1371/journal.pone.0184118.t001
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Table 2. Volatile organic compounds measured by ion-molecule reaction-mass spectrometry, with indications on whether molecules were
directly or indirectly calibrated, and which molecules were included in the regression models after comparison between environmental air and
exhaled air samples.
Measured molecules (97) Directly calibrated molecules (23) Indirectly calibrated molecules* (8) Molecules included in models (81)
CH4—Methane x x
C2H2—Acetylene x x
M27
M29 x
C2H6—Ethane x
CH2O—Formaldehyde x
CH4O—Methanol x
C2H3N—Acetonitrile x x
N2O—Nitrous Oxide x x
CH2O2—Formic Acid x
HNO2—Nitrous Acid x x
SO2—Sulfur Dioxide x
H2O—Water x
O2—Oxygen x
CO2—Carbon Dioxide x
NH3—Ammonia x x
M19 x
C2H4—Ethylene x x
NO–Nitric Oxide x
M31
M32
M33 x
H2S—Hydrogen Sulfide x
C3H6—Propene x x
M43 x
C2H4O—Acetaldehyde x x
M45 x
M48
M49
C4H6—Butadiene x x
C4H10O—Butanol x x
C4H8O—Methyl Ethyl Ketone x x
C3H6O—Acetone x x
C3H8O—n-Propanol x x
C2H4O2—Acetic Acid x x
M60 x
M61 x
M62 x
M63 x
M66 x
M67 x
C5H8—Isoprene x x
M69 x
M70 x
M71 x
C5H12—n-Pentane x x
(Continued )
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Table 2. (Continued)
Measured molecules (97) Directly calibrated molecules (23) Indirectly calibrated molecules* (8) Molecules included in models (81)
M73 x
M74 x
M75 x
M76 x
M77 x
C6H6—Benzene x x
M79 x
M80
M81 x
M82 x
M83 x
M84 x
M85 x
C6H14—n-Hexane x x
M87 x
M88 x
M89 x
M90 x
M91 x
C7H8—Toluene x x
M93 x
M94 x
M95 x
M96 x
M97 x
M98 x
M99 x
C7H16—n-Heptane x x
M101 x
M102 x
M103 x
M104 x
M105 x
M106 x
M107 x
M108 x
M109 x
M110 x
M111 x
M112 x
M113 x
M114 x
M115 x
M116 x
M117 x
M118 x
M119 x
(Continued)
Inflammatory bowel disease and volatile organic compounds in the exhaled breath of children
PLOS ONE | https://doi.org/10.1371/journal.pone.0184118 August 31, 2017 9 / 24
inflammatory process, while among the correctly classified two are found to be biliary duct
atresias and one was a choledochal cyst, the false positives include a Behc¸et’s disease, a chronic
intestinal pseudo-obstruction with ileostomy, and intestinal atresia, an infective ileitis, and a
graft-versus-host disease.
CD vs. UC
The model resulting from the attempt to separate CD from UC patients is based on 13 VOCs
plus age, and has the following formula (Table 6):
• predicted probability = 1/(1+exp(–(–5.178+3.444e–01Age +3.465e–03M29–4.342e–02Ace-
tonitrile +2.776e
–04NitrousOxide +4.540e–03Ammonia –1.162e–03Acetaldehyde +3.496e–02
MethylEthylKetone –6.994e–04M70–1.175e–02M74–2.663e–02M77 +1.301e–01M79–
9.094e–02M89–3.621e–01M90–2.669e–01M105–2.864e–01M107 +2.873e–01M114)))
Table 2. (Continued)
Measured molecules (97) Directly calibrated molecules (23) Indirectly calibrated molecules* (8) Molecules included in models (81)
M120 x
M121 x
M122 x
M123 x
* Calibrated through Benzene
https://doi.org/10.1371/journal.pone.0184118.t002
Fig 2. For the 81 molecules considered, difference between median values of alveolar and environmental air, with
values standardized to environmental air.
https://doi.org/10.1371/journal.pone.0184118.g002
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Fig 3. For the 81 molecules considered, VOCs profiles of median values of CD and UC patients compared to control
subjects, with values standardized to the median values of control subjects.
https://doi.org/10.1371/journal.pone.0184118.g003
Table 3. Variables and coefficients of the logistic regression model with outcome variables: Patients with inflammatory bowel disease vs. controls
(surgical + gastroenterological).
Variables Coefficient Std. Error 95% CI
(Intercept) -1.7610965 3.5213722 -8.030–2.522
Age (years) 0.4349465 0.1115950 0.408–0.718
Methane -2.1312841 1.0351154 -4.340 –-1.422
Nitrous Acid -0.2097137 0.1800298 -0.489–0.000
Acetic Acid 0.0011512 0.0007470 0.000–0.002
Ammonia 0.0004002 0.0014281 0.000–0.003
Propene 0.0058942 0.0048373 0.000–0.013
Acetaldehyde 0.0008888 0.0013211 0.000–0.004
Methyl Ethyl Ketone -0.0232373 0.0353011 -0.078–0.000
M69 -0.1222845 0.1114540 -0.324–0.000
M74 -0.0266032 0.0190338 -0.052–0.000
M76 0.1684388 0.1444729 0.010–0.469
M79 -0.0489416 0.0624447 -0.146–0.000
M81 0.0425079 0.0313594 0.028–0.120
M89 -0.0280041 0.0444448 -0.127–0.000
M99 0.0793372 0.0365851 0.036–0.144
M105 -0.1427593 0.1024486 -0.271–0.000
M107 -0.0132398 0.0956782 -0.234–0.000
M115 -0.0539797 0.1593523 -0.416–0.000
M118 0.1597398 0.4747905 0.000–1.188
https://doi.org/10.1371/journal.pone.0184118.t003
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Table 4. Performance of model comparing inflammatory bowel disease patients to controls, for sensitivity levels above 90% (in parenthesis, the
number of correctly classified cases).
Predicted
probability
Sensitivity in overall IBD
(n.67)
Specificity in overall controls
(n.167)
Specificity in gastro controls
(n.65)
Specificity in surgical controls
(n.102)
0.0538911 100.00% (67) 37.72% (63) 34.31% (21) 41.18% (42)
0.0763976 98.51% (66) 44.31% (74) 38.46% (25) 48.04% (49)
0.1269103 97.01% (65) 59.88% (100) 56.92% (37) 61.76% (63)
0.1808475 95.52% (64) 69.46% (116) 64.62% (42) 72.55% (74)
0.1880790 92.54% (62) 70.66% (118) 66.15% (43) 73.53% (75)
0.1990687 91.04% (61) 73.05% (122) 67.69% (44) 76.47% (78)
https://doi.org/10.1371/journal.pone.0184118.t004
Table 5. Diagnoses of the gastroenterological controls according to their classification in the model IBD vs. controls.
Correctly classified (42) False positives (23) Total (65) p*
Celiac disease 17 (40%) 5 (22%) 22 (34%) 0.173
Eosinophilic esophagitis 5 (12%) 1 (4%) 6 (9%) 0.411
Recurrent abdominal pain 1 (2%) 3 (13%) 4 (6%) 0.123
Constipation 3 (7%) 0 3 (5%) 0.547
Gastritis 1 (2%) 2 (9%) 3 (3%) 0.284
Probable latent celiac disease 1 (2%) 1 (4%) 2 (3%) 1.000
Functional dysphagia 2 (5%) 0 2 (3%) 0.536
Biliary duct atresia 2 (5%) 0 2 (3%) 0.536
Other 10 (24%) 11 (30%) 21 (32%) 0.058
* Fisher’s exact two-tailed test, considering one disease at the time vs. all others.
https://doi.org/10.1371/journal.pone.0184118.t005
Table 6. Variables and coefficients of the logistic regression model with outcome variables: Patients with Crohn’s disease vs. patients with ulcera-
tive—Colitis.
Variables Coefficient Std. Error 95%CI
(Intercept) -5.178 3.583 -1.065e+01 –-0.223
Age (years) 3.444e-01 3.431e-01 -4.371e-01–0.553
Ammonia 4.540e-03 5.657e-03 0.000–0.016
M29 3.465e-03 4.852e-03 0.000–0.013
Acetonitrile -4.342e-02 5.218e-02 -1.368e-01–0.002
Nitrous Oxide 2.776e-04 7.678e-04 0.000–0.002
Acetaldehyde -1.162e-03 2.567e-03 -7.022e-03–0.000
Methyl Ethyl Ketone 3.496e-02 3.267e-02 -3.278e-02–0.069
M70 -6.994e-04 2.479e-02 -6.398e-02–0.000
M74 -1.175e-02 3.867e-02 -9.873e-02–0.014
M77 -2.663e-02 3.456e-02 -8.980e-02–0.000
M79 1.301e-01 3.874e-01 0.000–1.049
M89 -9.094e-02 6.057e-01 -1.108–0.906
M90 -3.621e-01 1.112 -2.852–0.000
M105 -2.669e-01 6.501e-01 -1.656–0.000
M107 -2.864e-01 2.272e-01 -5.674e-01 –-0.011
M114 2.873e-01 4.202e-01 1.758e-03–1.236
https://doi.org/10.1371/journal.pone.0184118.t006
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The model had an AUC of 0.934 (95%CI: 0.880–0.988) and yielded a percentage of correctly
classified of 86.6% (S2 Fig). It had a sensitivity of 94% in detecting CD with a specificity of 76%
(Table 7). Symmetrically, the model had a sensitivity of 94% in detecting UC with a specificity
of 71%.
IBD vs. Gastroenterological controls
The fourth model aims at replicating a “real life” situation, in which a patient with gastrointes-
tinal symptoms needs to be diagnosed for IBD, and is therefore designed to distinguish IBD
patients from gastroenterological controls. The model is based on 15 VOCs plus age (Table 8):
• predicted probability = 1/(1+exp(–(–2.816 +4.580e–01Age –1.336Methane –3.995e–03 Ace-
tonitrile –2.463e–01NitrousAcid +1.285e–03AceticAcid +3.085e–03Propene +8.199e–04 Acet-
aldehyde –2.030e–02M67–3.135e–02M74 +7.298e–02M75–8.453e–02M79 +4.231e–02 M81–
5.543e–02M89 +2.516e–01M91 +5.698e–03M94–1.073e–01M105)))
Table 7. Performance of model comparing Crohn’s disease patients to ulcerative colitis patients (in parenthesis, the number of correctly classi-
fied cases).
Predicted probability Sensitivity in Crohn Disease (n.34) Specificity in UC controls (n.33) Correctly classified
0.3383077 100.00% (34) 72.73% (24) 86.57%
0.3876584 94.12% (32) 75.76% (25) 85.07%
0.5131218 88.24% (30) 81.82% (27) 85.07%
0.5658435 79.41% (27) 87.88% (29) 83.58%
0.6121589 76.47% (26) 90.91% (30) 83.58%
0.6433669 70.59% (24) 93.94% (31) 82.09%
0.7598559 52.94% (18) 100.00% (33) 76.12%
https://doi.org/10.1371/journal.pone.0184118.t007
Table 8. Variables and coefficients of the logistic regression model with outcome variables: Patients with inflammatory bowel disease vs. gastro-
enterological controls.
Variables Coefficient Std. Error 95% CI
(Intercept) -2.816 4.879 -13.330–1.833
Age (years) 4.580e-01 2.140e-01 0.315–0.938
Methane -1.336 8.425e-01 -2.651 –-0.107
Acetonitrile -3.995e-03 1.222e-02 -0.032–0.000
Nitrous Acid -2.463e-01 1.360e-01 -0.416 –-0.050
Acetic Acid 1.285e-03 8.897e-04 0.000–0.003
Propene 3.085e-03 4.451e-03 0.000–0.011
Acetaldehyde 8.199e-04 6.986e-04 0.000–0.002
M67 -2.030e-02 3.161e-02 -0.084–0.000
M74 -3.135e-02 2.683e-02 -0.073–0.000
M75 7.298e-02 1.361e-01 -0.216–0.206
M79 -8.453e-02 1.108e-01 -0.312–0.000
M81 4.231e-02 3.979e-02 0.004–0.122
M89 -5.543e-02 6.717e-02 -0.151–0.000
M91 2.516e-01 2.037e-01 0.000–0.572
M94 5.698e-03 8.080e-03 0.000–0.021
M105 -1.073e-01 9.137e-02 -0.236–0.000
https://doi.org/10.1371/journal.pone.0184118.t008
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The model had an AUC of 0.918 (95%CI: 0.873–0.963) (S3 Fig), and was able to identify
94% of IBDs (94% both for CD and UC patients), with a specificity of 65% (Table 9). Taking
the latter as the cut-off for sensitivity and specificity, we would still have 23 false positives
out of 65 gastro controls (Table 10). Once again, if the diseases are classified based on the
presence or plausibility of an ongoing inflammatory process, while among the correctly clas-
sified we find one intestinal atresia, the false positives include a Behc¸et’s disease, a chronic
intestinal pseudo-obstruction with ileostomy, a graft-versus-host disease, and an infective
ileitis.
IBD (CD + UC) vs. controls (surgical + gastroenterological) only with
directly or indirectly calibrated VOCs
Finally, the first model was replicated using only 21 unambiguously identified VOCs out of
the 81 initial molecules. This version of the model was finally based on 12 VOCs plus age
(Table 11):
• predicted probability = 1/(1+exp(–(–2.616+4.491e–01Age –7.421e–01Methane –4.356e–
03Acetonitrile +1.589e–04NitrousOxide –3.073e–01NitrousAcid +1.254e–03AceticAcid
+1.379e–03Ammonia –6.212e–03Ethylene +1.480e–03Acetaldehyde +4.226e–04Acetone
–6.135e–03Isopren+1.207e–01Toluene +8.734e–03n–Heptane)))
As expected, the AUC of this model was smaller than the one of the model comparing IBDs
with controls (AUC = 0.888; 95%CI: 0.843–0.933), but still quite high. The model was able to
detect 94% of IBDs with a specificity of 61% (54% for gastro controls and 66% for surgical
Table 9. Performance of model comparing patients with inflammatory bowel disease vs. gastroenterological controls, for sensitivity levels above
90% (in parenthesis, the correctly classified).
Predicted probability Sensitivity in IBD (n.67) Sensitivity in CD (n.34) Sensitivity in UC (n.33) Specificity in gastro controls (n.65)
0.1870422 100.00% (67) 100.00% (34) 100.00% (33) 46.15% (30)
0.2633038 97.01% (65) 97.06% (33) 96.97% (32) 55.38% (36)
0.2931387 95.52% (64) 94.12% (32) 96.97% (32) 58.46% (38)
0.3613650 94.03% (63) 94.12% (32) 93.94% (31) 64.62% (42)
0.3761519 92.54% (62) 94.12% (32) 90.91% (30) 66.15% (43)
0.4073664 91.04% (61) 94.12% (32) 87.88% (29) 69.23% (45)
https://doi.org/10.1371/journal.pone.0184118.t009
Table 10. Diagnoses of the gastroenterological controls according to their classification in the model IBD vs. gastro controls.
Correctly classified (42) False positives (23) Total (65) p*
Celiac disease 14 (33%) 8 (35%) 22 (34%) 1.000
Eosinophilic esophagitis 5 (12%) 1 (4%) 6 (9%) 0.411
Recurrent abdominal pain 2 (5%) 2 (9%) 4 (14%) 0.610
Constipation 3 (7%) 0 3 (5%) 0.547
Gastritis 2 (5%) 1 (4%) 3 (5%) 1.000
Probable latent celiac disease 1 (2%) 1 (4%) 2 (3%) 1.000
Functional dysphagia 2 (5%) 0 2 (3%) 0.536
Biliary duct atresia 2 (5%) 0 2 (3%) 0.536
Other 11 (26%) 10 (43%) 21 (32%) 0.175
* Fisher’s exact two-tailed test, considering one disease at the time vs. all others.
https://doi.org/10.1371/journal.pone.0184118.t010
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controls) (Table 12). If we take the latter as the cut-off for sensitivity and specificity, 30 out of
65 gastro controls result as being false positives (Table 13). Looking at the inflammatory pro-
cesses, while among the correctly classified we did not find any condition to report, the false
positives include a Behc¸et’s disease, a chronic intestinal pseudo-obstruction with ileostomy, a
graft-versus-host disease, and an infective ileitis.
Table 11. Variables and coefficients of the logistic regression model built with directly or indirectly calibrated VOCs, with outcome variable:
Patients with inflammatory bowel disease vs. controls (surgical and gastroenterological).
Variables Estimate Std. Error 95% CI
(Intercept) -2.616 1.848 -4.499–0.702
Age 4.491e-01 8.989e-02 0.3.04–0.551
Methane -7.421e-01 1.380 -3.952–0.000
Acetonitrile -4.356e-03 4.598e-03 -0.012–0.000
Nitrous Oxide 1.589e-04 2.466e-04 -0.000–0.000
Nitrous Acid -3.073e-01 5.877e-02 -0.363 –-0.208
Acetic Acid 1.254e-03 4.640e-04 0.000–0.002
Ammonia 1.379e-03 9.499e-04 0.000–0.002
Ethylene -6.212e-03 9.546e-03 -0.025–0.002
Acetaldehyde 1.480e-03 9.375e-04 0.000–0.003
Acetone 4.226e-04 5.043e-04 0.000–0.002
Isoprene -6.135e-03 2.162e-03 -0.009 –-0.003
Toluene 1.207e-01 8.372e-02 0.000–0.225
n-Heptane 8.734e-03 2.090e-02 0.000–0.061
https://doi.org/10.1371/journal.pone.0184118.t011
Table 12. Performance of the model with calibrated VOCs comparing patients with inflammatory bowel disease vs. controls (surgical and gastro-
enterological), for sensitivity levels above 90% (in parenthesis, the correctly classified).
Predicted
probability
Sensitivity in overall IBD
(n.67)
Specificity in overall controls
(n.167)
Specificity in gastro controls
(n.65)
Specificity in surgical controls
(n.102)
0.0325607 100.00% (67) 24.55% (41) 23.08% (15) 25.49% (26)
0.0713997 98.51% (66) 41.92% (70) 35.38% (23) 46.08% (47)
0.0984248 97.01% (65) 48.50% (81) 41.54% (27) 52.94% (54)
0.1314432 95.52% (64) 55.09% (92) 50.77% (33) 57.84% (59)
0.1516857 94.03% (63) 61.08% (102) 53.85% (35) 65.69% (67)
0.1624737 92.54% (62) 63.47% (106) 55.38% (36) 68.63% (70)
0.1762784 91.04% (61) 65.27% (109) 56.92% (37) 70.59% (72)
https://doi.org/10.1371/journal.pone.0184118.t012
Table 13. Diagnoses of the gastroenterological controls according to their classification in the model IBD vs. controls, built with directly or indi-
rectly calibrated VOCs.
Correctly classified (35) False positives (30) Total (65) p*
Celiac disease 14 (40%) 8 (27%) 22 (34%) 0.301
Eosinophilic esophagitis 3 (9%) 3 (10%) 6 (9%) 1.000
Recurrent abdominal pain 1 (3%) 3 (10%) 4 (14%) 0.328
Constipation 3 (9%) 0 3 (5%) 0.241
Gastritis 1 (3%) 2 (7%) 3 (5%) 0.591
Probable latent celiac disease 2 (6%) 0 2 (3%) 0.495
Biliary duct atresia 0 2 (7%) 2 (3%) 0.209
* Fisher’s exact two-tailed test, considering one disease at the time vs. all others.
https://doi.org/10.1371/journal.pone.0184118.t013
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Discussion
Among the VOCs identified by the first three models (based on 81 molecules listed in Table 2)
as relevant for specific pathological conditions, five had been calibrated and quantified: Acetic
Acid, Propene, Acetaldehyde, Acetonitrile and Methyl Ethyl Ketone (Table 14).
Acetic Acid, systematically named ethanoic acid, is commonly used in animal IBD models
to reproduce an IBD condition. [42–44] Recent literature suggests that Acetic Acid and similar
compounds are produced from pyruvic acid via pyruvate dehydrogenase, and that acetone
Table 14. Measured (the first 9 in the table) or hypothesized (the others)* VOCs that emerged as sig-
nificant in our models**.
IBD vs.
Ctrls
CD vs.
UC
IBD vs. Gastro
Ctrls
Age (years) + + +
CH4: Methane (MW 16) – –
NH3: Ammonia (MW 17) + +
C2H3N: Acetonitrile (MW 41) – –
C3H6: Propene (MW 42) + +
N2O: Nitrous Oxide (MW 44) +
C2H4O: Acetaldehyde (MW 44) + – +
HNO2: Nitrous Acid (47) – –
C2H4O2: Acetic Acid (MW 60) + +
C4H8O: Methyl Ethyl Ketone (MW 72) – +
M29: Methanimine (CH3N) +
M67: Pyrrole (C4H5N) –
M69: Isocyanatoethene (C3H3NO) or 2H–imidazolium (C3H5N2) –
M70: Cyclopentane (C5H10) or crotonaldeyde (C4H6O) –
M74: Propylhidrazyne (C3H10N2) or allyl mercaptane (C3H6S) – – –
M75: Trimethylamine N–oxide (C3H9NO) +
M76: Carbon disulfide (CS2) +
M77: Methyl nitrate (CH3NO3) –
M79: Pyridine (C5H5N) – + –
M81: 1 or 3–Methylpyrrole (C5H7N) + +
M89: 1–Nitropropane or 2–Nitropropane (C3H7NO2) or
2–(Dimethylamino)ethanol (C4H11NO)
– – –
M90: 2,2–Butanediol (C4H10O2) or ethoxyethanol (C4H10O2) –
M91: 3–Aminopropanethiol (C3H9NS) +
M94: Phenol (C6H6O) +
M99: Ethyl cyanoformate (C4H5NO2) +
M105: 2–(Ethylamino)ethanethiol or 2–(Dimethylamino)
Ethanethiol (C4H11NS)
– – –
M107: 2,6–Dimethylpyridine (C7H9N) – –
M114: 2,3,3–trimethylpentane (C8H18) +
M115: 1–Pyrrolidineethanol (C6H13NO) or 2–Methoxythiazole
(C4H5NOS)
–
M118: several molecules satisfy the inclusion criteria +
* In italics the compounds for which we could not find evidence in the literature.
** The last three columns show the molecules retained by each model in gray; the plus or minus sign
designates the sign of the coefficient in the regression model.
https://doi.org/10.1371/journal.pone.0184118.t014
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is also derived from the decarboxylation of pyruvic acid. [45] It is commonly assumed that
anaerobic metabolism is characterized by the non–specific production of fatty acids, such as
acetic acid which is the product of several pathogens including Staphylococcus aureus. [46] The
identification of the distinct metabolism of a specific bacteria is an important marker to deter-
mine the best pharmacological treatment.
One of the products that are derived directly from acetic acid is acetaldehyde, systematic
IUPAC name ethanal, that several reports identify as a significant marker of IBD. [30,47] Acet-
aldehyde is present in the intestinal colon and derives from an oxidative reaction caused by
several pathogens. Its antimicrobial activity in this area has been fully ascertained. [46,48]
Moreover, ethanal has already been described as a potential marker for the distinction between
the diagnoses of CD and UC. [49]
Propene, also known as propylene or methyl ethylene, is a hydrocarbon compound. [49]
Hydrocarbon compounds are known to be products of the metabolism of gram–positive and
negative bacteria. [51,52] The specific origin of propene, and consequently its role in IBDs, is
unknown, but it is likely that the degradation of propene occurs through the β–oxidation path-
way, as with other hydrocarbons (i.e. isoprene, 1-undecene or 1,3-butadiene).
Acetonitrile, a chemical compound also called ethanenitrile or ethyl nitrile, is mentioned in
a very interesting recent report as one of nine VOCs associated with the diagnosis of esoph-
ageal adenocarcinoma: [53] there are no data linking acetonitrile to the selective diagnosis
of IBDs, but this recent evidence should encourage further investigations to verify whether
this compound can be considered as a suitable marker of IBD. Moreover, acetonitrile was
included in an innovative study that had the objective of evaluating the VOCs profile of
patients depending on their body position (sitting, standing, supine, prone, left lateral and
right lateral) and cardiac output, in order to identify specific VOCs or clusters of VOCs that
could be considered as biomarkers. [54]
The last compound we found is Methyl Ethyl Ketone, also known as Butanone: it has never
been identified as a specific ketone in VOCs studies, but like other methyl ketones, such as ace-
tone, is produced during decarboxylation of fatty acid derives. [55] It is worth mentioning,
however, that the production of ketones through non–fermenting enterobacteriaceae has dif-
ferent origins. In fact, Xiao and Xu showed that acetoin, also called 3-hydroxybutadone, was
detected in non-fermenting Escherichia coli. [56] The synthesis of acetoin in Staphylococcus
has been associated with catabolic aspects of the metabolism.
Four other molecules were indirectly quantified without specific calibration: Methane,
Nitrous Oxide, Nitrous Acid, and Ammonia (Table 14).
Ammonia, a well investigated inorganic compound of nitrogen and hydrogen with formula
NH3, has been shown to be produced in greater quantities by the microbiota of IBD patients
compared to healthy individuals. [57–59] A possible hypothesis to explain this result is the pivotal
role of ammonia and other short–chain fatty acids in determining the onset or chronicity of IBD,
since the microbiota of IBD patients synthesizes large amounts of these compounds. [50,57]
It is worth noting that published studies report lower values of ammonia in UC patients
compared to controls. [29] This evidence is in contrast with that reported by other studies,
[57] and helps emphasize how results can vary in populations that differ in terms of average
age and number of controls and patients. [60,61]
Moreover, recently published studies have shown that ammonia is involved in protein
metabolism, with the consequent production of ammonium ions that can be converted to
nitric oxide in the presence of nitric oxide synthase. [62,63] NO metabolites (nitrate/nitrite)
are significantly increased in IBD, and NO levels have a great potential as biomarkers for the
screening of IBD. [61,64–67]
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The interest on NOX compounds is supported by several articles that agree in attributing to
these compounds the role of biomarkers of bowel diseases. [68–70]
Finally, the production of methane in the distal colon is known to be due to endogenous
(epithelial cells and dead bacteria) and exogenous (complex carbohydrates and non–digestible
disaccharides) compounds. [71] Methane is an important biomarker of bacterial overgrowth
typical of the IBD condition: several experimental studies tried to explain the mechanisms
underlying the link between IBD and the abnormal biosynthesis of methane, [72,73] but to
date this relation remains unclear. [74]
In conclusion, several VOCs show to be promising biomarkers for the non-invasive detec-
tion of IBD, thereby warranting further studies to assess whether the technical aspects of our
experimental protocols on VOCs analysis can to be improved in the light of recent data in lit-
erature highlighting the importance of optimal sample collection. [75–77]
Some uncertainty remains for the other VOCs because more compounds—or fragments—
may have the same MW. Following us on the hypothesis that these molecular weights refer to
primary molecules, and not to fragments produced during the soft ionization and before MS
detection, we compared our results with data from the literature on the composition of human
alveolar air. MW 114 could correspond to 2,3,3–trimethylpentane, detected by Filipiak et al.
[78] in the headspace of lung–cancer cells together with Acetaldehyde, MEK, Hexanal, Acro-
lein, and other aliphatic hydrocarbons. The same applies to MW 76, that could be identified
as carbon disulphide, as detected by Navaneethan et al., [79] while MW 77 could be Methyl
Nitrate, a product of oxidative stress reaction, as suggested by Minh et al. [80] MW 107 could
correspond to 2,6–Dimethylpyridine, which is known to be a fragment of lysozyme [81]. MW
75 could be Trimethylamine N–oxide, a product of the microbiota, and the result of the con-
version of phosphatidylcholine, a major component of cell membranes. [82–85]
For the molecules with MW 29, 67, 69, 70, 74, 79, 81, 89, 90, 91, 94, 99, 105, 115 and 118
Dalton, no data were available in literature. Thus, in order to better characterize these prod-
ucts, we looked at all the molecules with the above mentioned molecular weights reported by
PubChem (http://pubchem.ncbi.nlm.nih.gov) or by the ChemSpider free–on–line database
from the Royal Society of Chemistry (http://RSC.org; http://www.chemspider.com).
Among the reported molecules we excluded:
• Molecules of clear industrial origin (for example products containing chlorine atoms or fluo-
rine, bromine, etc.);
• Molecules with ester linkage (as they are easily ionisable in the blood and they cannot be
expelled with the alveolar air);
• Highly reactive molecules, which show instability in the biological matrix (i.e. free radicals);
• Molecules with a boiling point above 150˚C, with high steam pressure (above 20 mm/Hg at
25˚C) and low enthalpy of vaporization (>20 KJoule/mol): their concentration in the alveo-
lar air should be so low that we should not be able to detect them with our equipment.
Reported in italics in Table 14 are molecules that, for their physical/chemical properties
and based on the criteria identified above, could be associated with the molecular weights we
identified.
We also evaluated if the performance of our models in correctly identifying CD and UC
patients was affected by the level of activity of the diseases (by PCDAI and PUCAI respectively)
and found no relevant relation (data not shown).
The main weakness of our study is the uncertainty in the definition of some of the molecules
included in the final predictive models. Another weakness is the impossibility to recruit only CD
Inflammatory bowel disease and volatile organic compounds in the exhaled breath of children
PLOS ONE | https://doi.org/10.1371/journal.pone.0184118 August 31, 2017 18 / 24
and UC cases at onset, in the absence of an ongoing therapy that could partially affect the results
of the regression models. We are aware that ideally suspect IBD cases should have been recruited
at their first visit, and only subsequently divided into cases and controls, replicating a “real life”
clinical situation. Selecting only suspicious cases at onset, however, would have required exceed-
ingly long recruitment procedures. The positive aspect of our approach is that untreated cases
(four CD and two UC) performed very well with all models, with predicted probabilities much
higher than any possible cut–off we applied. This means that the effect of therapies, which are
too complex and heterogeneous to be taken into account, is limited. The advantage of such a
wide range of different therapies translates into models which are not directly affected in terms
of outcome, although therapies almost certainly introduce some “noise”.
As specified in the Methods section, children had been fasting at least since midnight. Even
if the prior evening meal did affect the colonic bacterial metabolism, and consequently alter
the VOCs profile, we have no reason to believe meals were significantly different among the
groups considered. Nevertheless, future studies might consider the possibility of standardizing
the evening meal. We need to mention, however, that IBD patients might have different feed-
ing patterns which could influence the composition of the microbiota, and consequently the
VOCs pattern. In our study we did not correct for this aspect.
The main strength of the study lies in the use of a very precise instrument for the detection
of VOCs. Our study clearly demonstrates that pediatric IBD patients (and CD patients in par-
ticular) have identifiable alveolar air VOCs patterns that differ from those of healthy subjects
and gastroenterological controls. In addition, our models show that CD and UC present differ-
ent patterns, emphasizing the different pathogenesis and clinical picture of the two diseases.
The results of the analysis of the false positives suggest that there might be something in
common between IBDs and the false positives among the gastrointestinal controls, in terms
of ongoing inflammatory processes. In fact, if we compare the false positives to the correctly
classified in this group, we notice that the false positives have proportionally more severe and
far more complex inflammatory clinical pictures. At this stage, however, this can only be a
hypothesis, and certainly the intestinal microbiota, and/or the interaction between inflamma-
tion and the microbiota, could also play a role in determining the VOCs pattern.
In our opinion this study should be considered as a promising starting point. The creation
of predictive models based on VOCs profiles, with the use of high precision instruments and
advanced statistical methods, can contribute to the development of new non–invasive, fast and
relatively inexpensive diagnostic tools, designed specifically for children, with very high sensi-
tivity and specificity. It also represents a crucial step towards gaining further insights into the
etiology of IBDs through the analysis of specific molecules which are the expression of the par-
ticular metabolism that characterizes these diseases. New prospective studies, following IBD
patients from onset to post-treatment, should also be developed in order to study the relation-
ship between VOCs profile and response to therapy.
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